Skip to main content
SpringerLink
Log in

DGHO-Empfehlung

Ruxolitinib nun Standard bei Myelofibrose

  • infopharm
  • Published:
Info Onkologie Aims and scope

Die DGHO empfiehlt den JAK1/2-Inhibitor Ruxolitinib in ihrer Leitlinie zur symptomatischen Therapie der Myelofibrose als Standardtherapie.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Meet the Experts „Myelofibrose & MDS“ anlässlich der DGHO-Jahrestagung, Hamburg, 11. Oktober 2014; Veranstalter: Novartis Pharma

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Andrea Warpakowski

Authors
  1. Andrea Warpakowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Warpakowski, A. Ruxolitinib nun Standard bei Myelofibrose. Info Onkol. 18, 50 (2015). https://doi.org/10.1007/s15004-015-0750-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-015-0750-8

Search

Navigation